The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure.

Trial Profile

The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPHASIS-HF
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Mar 2017 Results of post hoc analysis published in the European Journal of Heart Failure
    • 02 Feb 2016 Results of subgroup analysis published in the European Journal of Heart Failure
    • 12 May 2012 Planned number of patients changed from 3100 to 3102 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top